AG-858
AG-858 Uses, Dosage, Side Effects, Food Interaction and all others data.
AG-858 (autologous heat-shock protein 70 peptide vaccine) isa recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.
AG-858 is an investigational personalized vaccine designed to treat cancer while minimizing the side effects that are often associated with other treatment options. Patients undergo a blood-filtering process called leukapheresis, during which white blood cells are collected. The white blood cells are sent to Antigenics so that the personalized vaccines can be made. Vaccines provoke the body’s natural disease-fighting response. A vaccine that is made from the patient’s own cancerous cells is designed to contain the particular cancer’s ‘fingerprint.’ Injection of the AG-858 vaccine may cause the body to attack any cells bearing this cancer fingerprint.
| Trade Name | AG-858 |
| Generic | AG-858 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in leukemia (myeloid).
How AG-858 works
Under normal conditions, heat shock proteins are not found outside the cell. But if a cancerous or infected cell has become so sick that it dies and its membrane bursts, all of the cell’s contents spill out, including heat shock proteins that are bound to peptides. These extracellular HSPs send a very strong ‘dange r signal’ to the immune system, instructing it to destroy the other diseased cells. This is how it works:
* A sick cell dies and ruptures, spilling out the HSP-peptide complexes.
* These extracellular complexes of HSPs and peptides are detected by circulating immune system cells called antigen-presenting cells (APCs). These APCs include cells called macrophages and dendritic cells.
* The HSP complexes bind the CD91 receptor on the APC cell surface. The APC can then take in the HSP complexes.
* Once the APCs have taken in the HSP complexes, they travel to the lymph nodes, which are clusters of immune system tissue that are distributed throughout the body.
* In the lymph nodes, the APCs take the peptides that were associated with the HSPs and re-present them on the APC cell surface. These peptides are antigenic — meaning that they can stimulate an immune response.
* In the lymph nodes, specialized immune cells called T cells ‘see’ these peptides and are then programmed to seek out cells bearing these specific, abnormal peptides.
* Because every person and every cancer is different, the unique repertoire of antigenic peptides represents that individual patient’s specific cancer’s ‘fingerprint.’ The T cells are activated to target and destroy cancer cells bearing this fingerprint.
Toxicity
Well-tolerated — it’s designed to leave your healthy cells alone so the side effects of most conventional cancer treatments are minimized
Innovators Monograph
You find simplified version here AG-858
